Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.
about
Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancerTargeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?Albumin-bound paclitaxel in solid tumors: clinical development and future directionsPhase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP studyClinical Translation of Nanomedicine.Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group studyAn open-label, multicenter, phase I trial of a cremophor-free, polymeric micelle formulation of paclitaxel combined with carboplatin as a first-line treatment for advanced ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG-3016).Multiscale tumor spatiokinetic model for intraperitoneal therapyComparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systemsTargeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer.Highly selective and sensitive assay for paclitaxel accumulation by tumor cells based on selective solid phase extraction and micro-flow liquid chromatography coupled to mass spectrometryAntiangiogenic activity of sterically stabilized liposomes containing paclitaxel (SSL-PTX): in vitro and in vivo.Novel water-soluble polyurethane nanomicelles for cancer chemotherapy: physicochemical characterization and cellular activities.A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignanciesHigher rate of skin rash in a phase II trial with weekly nanoparticle albumin-bound paclitaxel and cisplatin combination in Chinese breast cancer patientsSafety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer.Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel.Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval.Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy.Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice.Physicochemical properties and biocompatibility of a polymer-paclitaxel conjugate for cancer treatment.Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.nab-Paclitaxel dose and schedule in breast cancerPharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patientsA population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979)Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors.Biodistribution and pharmacokinetics of a telodendrimer micellar paclitaxel nanoformulation in a mouse xenograft model of ovarian cancerWeekly nab-Paclitaxel in Metastatic Breast Cancer - Summary and Results of an Expert Panel Discussion.4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.A cremophor-free self-microemulsified delivery system for intravenous injection of teniposide: evaluation in vitro and in vivoA critical review of lipid-based nanoparticles for taxane delivery.Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic studyQuantitative determination of total and unbound paclitaxel in human plasma following Abraxane treatment.Clinical outcomes of women with metastatic breast cancer treated with nab-paclitaxel: experience from a single academic cancer centre.A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer.Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetrationWeekly intravenous nanoparticle albumin-bound paclitaxel for elderly patients with stage IV non-small-cell lung cancer: a series of 20 cases.Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced non-small-cell lung cancer.Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time?A comprehensive survey of the mutagenic impact of common cancer cytotoxics
P2860
Q24657308-AD9E4F9F-FB7D-4772-AA6A-127274FD1186Q26745420-750F89DC-0C7F-4112-9B78-49B401356C69Q26798674-75F68132-D99B-45B5-8971-E45806DA678BQ28359347-AF68BA8A-F47D-479D-9A79-A4B5D6C3C952Q30355939-038D57B9-8147-43D5-9D06-796C35B949B5Q30443910-BDF2F167-023C-42CA-83E8-0250896E6B45Q33563915-EBD4D303-3E6D-429A-ADCF-0EE6FD227C93Q33574144-1AEA5147-0488-4670-BE12-E4E3FB5F5C87Q33611516-E01462BA-FCA4-4730-94F7-51BA6C849524Q33916040-39F3628B-338D-40C9-948C-E9EC1FA0FF2BQ33958472-48A1588F-610A-4F8E-A8F7-F3BC0E5837E2Q33985966-D73DEAC1-26E4-4D87-BFAA-69F7FEDED6C5Q34119493-9D098D4D-D185-4943-850A-A3388BE0E3DDQ34530485-CE069FF9-CDC8-48E7-9F16-E3F34FD99C91Q34713757-F2C4933E-7A93-4324-83E0-CCA619BA41D6Q34965672-DC185466-57EC-4B93-85A9-4FA88A18CD14Q34996710-CD334A7D-4D23-45D3-BEB6-00328F7FEBD2Q35128729-4AF331B3-B44C-43C8-BDB8-0C9DDA7051DEQ35166688-08578E43-C6FF-4C1B-8BA9-2B83709C77B0Q35178040-5B3E1E08-5CA6-400B-BFE5-A940AC0427F2Q35488326-B4BC66FC-B7A1-4A00-ADD6-B8D7884388D3Q35507680-4A905C24-1E36-4E03-8A59-E73D24DB77E0Q35734193-5200873A-64BB-4DB4-8218-0688986E448BQ35803848-3C795DF1-BDEE-4E8F-90B7-B64A82FA334EQ35825630-4C2260D3-96C2-450E-A4E4-281B00C324BEQ35869447-9D7D28D0-2F9F-417F-8EFC-3B5A6138054DQ35962145-8CE49826-673C-40FA-AE3B-1659B524A2E8Q36036125-300E586D-967A-4C73-937F-E3BBEEC28832Q36072512-ED987F7D-DFA2-4AB3-96E8-90A38A2BF5B4Q36195154-AEC9C9B3-7FAF-4C20-A0AE-2F81C1E8A977Q36360764-B9A73694-CA34-48DC-8B77-B4B779E66437Q36388079-8D3181FD-5964-49C8-B043-D1299D0628F6Q36484911-BCCCC910-458F-4A78-8D6F-B6324EEB06DCQ36568558-54F9E0B4-48DD-483E-9888-C7098B771261Q36611637-EEEC75CF-6617-4910-8A4E-9E875BE821B5Q36621587-238E9AC9-73BA-4CFA-A29A-E88AAB7101E8Q36680050-81EB5779-40F5-452C-8BC4-B419B4595F70Q36767660-2BB8ED2E-12ED-4537-94B4-1B6EC7F9F3CFQ36860835-FB832E26-47B9-4904-9D52-87554FC97D99Q36886849-72517EEC-6500-4286-A75D-6F91D90C214F
P2860
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Cremophor EL-mediated alterati ...... pharmacokinetic implications.
@ast
Cremophor EL-mediated alterati ...... pharmacokinetic implications.
@en
type
label
Cremophor EL-mediated alterati ...... pharmacokinetic implications.
@ast
Cremophor EL-mediated alterati ...... pharmacokinetic implications.
@en
prefLabel
Cremophor EL-mediated alterati ...... pharmacokinetic implications.
@ast
Cremophor EL-mediated alterati ...... pharmacokinetic implications.
@en
P2093
P1433
P1476
Cremophor EL-mediated alterati ...... l pharmacokinetic implications
@en
P2093
Gelderblom H
Sparreboom A
de Bruijn P
van Zuylen L
P304
P407
P577
1999-04-01T00:00:00Z